Eli Lilly’s best-selling weight loss drug, Zepbound (tirzepatide), has scored again, this time in a late-stage trial alongside the company’s plaque psoriasis drug, Taltz (ixekizumab). During the Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results